This contract expires in 324 days (Sep 16, 2027).
NOVOGENE CORPORATION INC - PHARMACOGENOMIC ANALYSIS SERVICES OF PARTICIPANTS ENROLLED IN THE STAR-B RANDOMIZED CLINICAL TRIAL OF SEMAGLUTIDE FOR ALCOHOL USE DISORDER
Key Details
Description
PHARMACOGENOMIC ANALYSIS SERVICES OF PARTICIPANTS ENROLLED IN THE STAR-B RANDOMIZED CLINICAL TRIAL OF SEMAGLUTIDE FOR ALCOHOL USE DISORDER
Context & Analysis
On Sep 21, 2026, Department of Health and Human Services obligated $24,999.99 to NOVOGENE CORPORATION INC for pharmacogenomic analysis services of participants enrolled in the star-b randomized clinical trial of semaglutide for alcohol use disorder. The award is classified under NAICS 541380 — TESTING LABORATORIES AND SERVICES. Competition extent: not competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SACRAMENTO, CA. The contract is scheduled through Sep 16, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541380 — related awards are listed below.
Contractor Information
Similar Awards
TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAM
GINKGO BIOWORKS, INC.
$78.0M
WASTEWATER SURVEILLANCE TESTING
VERILY HEALTH INC.
$42.3M
INNOVATION FUNNEL FOR COVID-19 - VALIDATION CENTER
EMORY UNIVERSITY
$41.2M
STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS.
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
$38.8M
CENTRALIZED OMICS RESOURCE (CORE) YEAR 5
THE BROAD INSTITUTE, INC
$36.4M
Stay Updated
Get notified about new opportunities matching your interests.